sofosbuvir/velpatasvir / Generic mfg. - LARVOL DELTA

Evaluation of serum MicroRNAs and HCV Core antigen as predictive and diagnostic biomarkers for chronic hepatitis C management in Iraqi patients: comparison with PCR-based detection. (PubMed, J Genet Eng Biotechnol) - "Serum miR-122 and HCV core antigen are clinically relevant complementary biomarkers for the diagnosis of chronic hepatitis C and for predicting on-treatment virological response in Iraqi patients. Although the microRNAs are themselves quantified by RT-qPCR, these findings support wider implementation of miRNA- and HCV core antigen-based testing as lower-cost complements, and in the case of HCV core antigen a potential alternative, to HCV RNA PCR for diagnosis and treatment monitoring in resource-constrained settings."

Biomarker • Journal • Hepatitis C • Infectious Disease • Inflammation • MIR122 • MIR191 • MIR221

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. (PubMed, J Clin Oncol) - "HCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting."

Journal • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Inflammation • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Expanding the Intestinal Donor Pool: Use of Hepatitis CâPositive Donors in Small Bowel Transplantation (ACG 2026) - "DAA therapy (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) was initiated between postoperative days 3â10. These findings support the selective use of HCV-positive donors to expand the intestinal graft pool. Larger multicenter cohorts with extended follow-up are needed to validate long-term safety and optimize antiviral protocols."

Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplant Rejection • Transplantation

Trends in Medicare Part D and Medicaid Utilization and Spending on Hepatitis C Direct-Acting Antiviral Agents: 2019â2024 (ACG 2026) - "Glecaprevir/pibrentasvir declined 75.0% ($660M to $165M) and glecaprevir/pibrentasvir was the dominant agent, with spending declining from $1.19B to $692.9M (-41.9%) and claims falling 33.0% (80,940 to 54,252). Substantial declines in utilization and inflation-adjusted spending were observed across both programs. In Medicare Part D, sofosbuvir/velpatasvir remained the most utilized DAA in 2024 (31,431 claims; -24.4%), with spending falling 39.1% ($1.24B to $758M). Ledipasvir/sofosbuvir and elbasvir/grazoprevir experienced near-complete market exit, with spending reductions of 96.1% and 97.3%, respectively."

Medicaid • Medicare • Reimbursement • US reimbursement • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Real-World Effectiveness of Direct-Acting Antivirals in Mexican Patients With Chronic Hepatitis C: A Multicenter Study by Cirrhosis Status (ACG 2026) - "The most frequent genotypes were 1A (35.2%) and 2 (19.8%), and the most commonly used regimen was sofosbuvir/velpatasvir (54.2%)... A total of 253 patients were included. Median age was 56 years, 55.3% were female, and 82.2% were treatment-naïve. Cirrhosis was present in 137 patients (54.1%)."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Hepatitis C Reactivation After Sustained Virologic Response in HIV-Positive Patient on Long-Acting Injectable Cabotegravir and Rilpivirine (ACG 2026) - "The patient was discontinued from the cabotegravir / rilpivirine and was started on oral bictegravir/emtricitabine/tenofovir alafenamide for treatment of his HIV. Additionally, the patient was prescribed 12 weeks of oral sofosbuvir/velpatasvir for treatment of his hepatitis C. The patient completed treatment and improved clinically...It is unsafe for patients to have long acting injectables without close follow up. Figure: Right Upper Quadrant Ultrasound showing "starry sky" appearance of the liver."

Clinical • Autoimmune Hepatitis • Genetic Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Movement Disorders

Multiple Duodenal Ulcers: What Could Be the Cause? (ACG 2026) - "She later returned with dyspnea, hematochezia, and worsening symptoms after starting Epclusa and entecavir, avoiding PPI therapy due to known drug interactions. Figure: Figure 2. EUS-guided biopsy of the peri-pancreatic lymph node and gastric wall."

B Cell Lymphoma • Cardiovascular • Crohn's disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Hypertension • Immunology • Indolent Lymphoma • Infectious Disease • Inflammatory Bowel Disease • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Peptic Ulcer • Pulmonary Disease • Solid Tumor • GAST

A Curious Case of Hepatitis C Through Cadaveric Transmission: A Case Report (ACG 2026) - "While previously postulated as a mode of transmission, we were unable to identify a published case report of confirmed hepatitis C transmission from cadaver exposure. Following his infectious course, it is also of interest to note that, although he was prescribed sofosbuvir/velpatasvir on discharge, he was unable to obtain the medication and subsequent undetectable HCV viral load and normalization of liver enzymes suggests spontaneous viral clearance."

Case report • Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Concurrent Immune-Related Hepatitis and Pancreatitis in a Patient Receiving Atezolizumab for Hepatocellular Carcinoma (ACG 2026) - "Case Description/ A 78-year-old female with a past medical history of metastatic breast cancer, chronic hepatitis C on Epclusa, HCC on atezolizumab/bevacizumab, initially presented with altered mental status...Following goals-of-care discussions, the patient elected for inpatient hospice and was discharged on prednisone 40 mg daily with a planned 4-week taper...Prompt recognition, discontinuation of the drug, and starting corticosteroid therapy are essential for management. Figure: Trends In Liver and Pancreatic Chemistries throughout Hospitalization"

Clinical • Breast Cancer • Cognitive Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Pancreatitis • Solid Tumor

Prior Decompensation Events and Outcomes in Patients Treated for Cirrhosis Secondary to Chronic Hepatitis C (ACG 2026) - "This retrospective study evaluated patients' decompensating events prior to initiating treatment and outcomes after SVR (sustained virologic response) using the current guideline recommended treatment regimens of sofosbuvir-velpatasvir (sof-vel) and ledipasvir-sofosbuvir (led-sof) with the addition of ribavirin (rbv). The study comprised a total of 41 patients (32 males). Prior to treatment, 3 patients were Child-Pugh class C and the remaining were Child-Pugh class B, with a mean MELD of 14.5 ± 4.8 . 22 patients (53%) were treated with sof-vel-rbv, 5 with led-sof-rbv, 8 with led-sof, 6 with sof-vel."

Clinical • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Solid Tumor

AI-Powered Hepatitis C Single-Encounter Test-and-Treat (clinicaltrials.gov) - P4 | N=35 | Not yet recruiting | Sponsor: Patrick Grace

New P4 trial • Hepatitis C • Infectious Disease • Inflammation

Determinants of Treatment Adherence in Hepatitis C Patients in a Public Sector Setting in India. (PubMed, Am J Trop Med Hyg) - "Attrition remained a major barrier to HCV care, and it was associated with intravenous drug use, decompensated cirrhosis, the sofosbuvir/velpatasvir regimen, and longer treatment duration. Adherence improved over time in follow-up, and good adherence was associated with good treatment outcomes."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir-Velpatasvir. (PubMed, Viruses) - "Based on the literature and real-world data, managing polypharmacy in HCV patients with comorbidities is effective and well-tolerated, provided thorough drug review, potential DDI analysis, proactive monitoring, and coordinated multidisciplinary care are ensured. DAAs have dramatically improved the management of HCV patients; however, they have different DDI profiles that should be carefully checked. SOF/VEL has been shown to be associated with minimal clinically relevant interactions and offers a simple dosing regimen. DAA treatment is strongly advised in HCV comorbid patients not only to cure HCV but also to improve the course of comorbidities, provided that DDIs are no longer considered mere minor details."

Journal • Review • Cardiovascular • CNS Disorders • Diabetes • Hepatitis C • Infectious Disease • Mental Retardation • Metabolic Disorders • Oncology • Psychiatry • Transplantation

Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model. (PubMed, Trop Med Infect Dis) - "Eligible patients received pangenotypic sofosbuvir/velpatasvir for 12 weeks, with ribavirin added for cirrhosis. Among 6719 evaluable for SVR12, 6474 (96.4%) achieved cure. This simplified, domestically financed, decentralized test-to-treat model achieved WHO-target-level diagnosis, treatment, and cure rates at provincial scale, offering a scalable framework for HCV micro-elimination in low- and middle-income countries."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) (clinicaltrials.gov) - P4 | N=30000 | Recruiting | Sponsor: Oswaldo Cruz Foundation | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Head-to-Head • HEOR • Trial completion date • Trial primary completion date • Hepatitis C • Infectious Disease • Inflammation

Re-Engagement of Hepatitis C Patients Lost to Follow-Up: A Multicenter Study from Argentina (PubMed, Acta Gastroenterol Latinoam) - "Antiviral therapy began in 224 patients: sofosbuvir/velpatasvir 70.1% and glecaprevir/pibrentasvir 29.9%. Complementary case-finding plus a two-visit pathway enabled effective re-engagement and timely treatment, achieving near-universal SVR. This scalable model supports HCV micro-elimination across public hospital networks."

Clinical • Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Transplantation

Short Perioperative Antiviral Prophylaxis for Hepatitis C Viremic Donor Kidney Transplantation: Outcomes in 204 Recipients. (PubMed, Transplantation) - "Seven-day perioperative sofosbuvir/velpatasvir prophylaxis achieved SVR after prophylaxis alone in >92% of D+/R- kidney transplant recipients, with favorable 1-y clinical outcomes. Given the nonstructural protein 5A resistance-associated substitutions observed, we have transitioned to 7-d glecaprevir/pibrentasvir prophylaxis; outcomes will be reported via the REFORM-HEPC registry. These findings provide real-world evidence supporting the feasibility of short-course antiviral prophylaxis in HCV-viremic donor kidney transplantation."

Journal • Hepatitis C • Infectious Disease • Inflammation • Transplantation

Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study. (PubMed, J Clin Transl Hepatol) - "In this study, we aimed to assess the safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) and the pre-treatment of tenofovir alafenamide fumarate (TAF) on HBV reactivation in HBV/HCV coinfected patients...SOF/VEL effectively achieves a sustained virologic response and improves liver function, with an acceptable safety profile in chronic HBV/HCV coinfected patients, including those with compensated cirrhosis, who achieved modest improvement in non-invasive fibrosis indices. Pre-administration of TAF may mitigates the risk of HBV reactivation in this population."

Clinical • Journal • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • AFP

Outcomes After 4-Week Course of Sofosbuvir/Velpatasvir Therapy in Hepatitis C Seronegative Recipients of Kidneys From Hepatitis C Viremic Deceased Donors. (PubMed, Clin Transplant) - "A 4-week SOF/VEL prophylaxis regimen coupled with HCV RNA surveillance and treatment appears to be safe and effective in a Veterans Affairs population."

Journal • Retrospective data • Hepatitis C • Infectious Disease • Inflammation • Transplant Rejection • Transplantation

Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II. (PubMed, Front Med (Lausanne)) - "After unsuccessful therapy with hydroxychloroquine, treatment with sofosbuvir/velpatasvir achieved sustained virologic response, resolution of skin lesions, and marked ferritin reduction. This case illustrates that viral and metabolic stressors can trigger PCT in CDA II patients with possible hepatic involvement, underscoring the importance of recognizing combined genetic and infectious factors in rare hematologic disorders."

Journal • Anemia • Genetic Disorders • Hematological Disorders • Hepatitis C • Infectious Disease • Inflammation • Metabolic Disorders • Rare Diseases • SEC23B

Real-world effectiveness of sofosbuvir/velpatasvir retreatment in people living with HIV and recurrent hepatitis C (AIDS 2026) - "Although international guidelines recommend sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) or glecaprevir/pibrentasvir for retreatment, these regimens are unavailable in Colombia. SOF/VEL retreatment in DAA-experienced PLWH achieved clinically meaningful SVR12, although lower than rates reported for guideline-recommended salvage regimens. Outcomes were primarily influenced by behavioral and host factors rather than virological resistance. Advancing HCV micro-elimination in PLWH with recurrent infection in resource-limited settings will require integrated strategies combining optimal HIV suppression, adherence support, sexual-health interventions, and harm-reduction programs."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Successful treatment of vertically acquired Hepatitis C in a child using direct-acting antiviral therapy administered via gastrojejunal tube: A case report. (PubMed, JPGN Rep) - "We report the case of a medically complex child with vertically acquired HCV who achieved sustained virologic response at 12 weeks (SVR12) following treatment with crushed sofosbuvir/velpatasvir (SOF/VEL) administered to a patient with a gastrojejunal tube...This case supports the feasibility and effectiveness of enteral DAA administration using crushed SOF/VEL in children with complex medical needs. Further research and formal guidance are needed to optimize treatment strategies for pediatric patients with similar challenges."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Pediatrics

Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long-Standing Chronic Hepatitis C Virus Infection. (PubMed, J Med Virol) - "Seven individuals received glecaprevir/pibrentasvir (GLE/PIB) and one individual received sequential sofosbuvir/velpatasvir/ribavirin followed by GLE/PIB. Cases in this study also show that HCV-infected chimpanzees, like humans, are susceptible to HCC in the late stages of chronic infection. We recommend lifelong HCC surveillance for all HCV-exposed chimpanzees."

Journal • Fibrosis • Hepatitis C • Hepatocellular Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor

Improving immunotherapy response with direct-acting antiviral therapy in patients with advanced hepatocellular carcinoma and chronic hepatitis C virus infection. (ASCO 2026) - P4 | " In this open-label single-arm clinical trial (NCT05717400), patients with HCV-related HCC received atezolizumab plus bevacizumab and DAAs (sofosbuvir/velpatasvir [SV] or SV/voxilaprevir [SVV]). Early DAA therapy after ICT in patients with advanced HCC was safe and resulted in enhanced CD4⁺ and CD8⁺ T-cell responses with excellent virologic control but did not impact tumor response. Larger clinical trials are warranted to determine whether HCV clearance with DAA therapy enhances ICT response in patients with HCV-related HCC."

Clinical • IO biomarker • Metastases • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor • CD4 • CD68 • CD69 • CD8 • ICOS

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial. (PubMed, J Hepatol) - P=N/A | "Prognostic scores could help target interventions more efficiently; greater adherence support and/or novel interventions are needed to improve SVR for the highest risk."

Journal • CNS Disorders • Hepatitis C • Infectious Disease • Inflammation